+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population



KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population



Human Immunology 73(9): 927-931



Non-small cell lung carcinoma (NSCLC) is a multifactorial disease influenced by both environmental and genetic factors. Here, we examined whether the repertoire of genes encoding killer immunoglobulin-like receptors (KIR) and genes for their ligands, C1/C2 and Bw4, may affect a susceptibility to NSCLC and response to treatment. We typed 269 NSCLC patients and 690 healthy control individuals for KIR genes and for their ligands. KIR genes were not associated with NSCLC. C1C2 genotype was less frequent whereas both C1C1 and C2C2 homozygotes were more frequent in patients than in controls (χ(2)=7.73; df=2; p=0.021). Patients positive for KIR2DL2 and KIR2DS2 gene and homozygous for the C1 ligand were 6 times more likely to respond to treatment than those with other genotypes (p=0.034). In accordance with this, patients with the KIR2DL2+/KIR2DS2+, C1C1 genotype survived longer than others (p=0.0094). Median survival was 23months for KIR2DL2/2DS2/C1C1-positive patients, but only 10 months for those with other genotypes.

(PDF emailed within 0-6 h: $19.90)

Accession: 054034238

Download citation: RISBibTeXText

PMID: 22836042

DOI: 10.1016/j.humimm.2012.07.323


Related references

Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. Journal of Thoracic Oncology 4(8): 994-1001, 2009

Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era. Clinical Lung Cancer 15(3): 202-206, 2014

Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 33(10): 1437-1440, 2006

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology 23(11): 2513-2520, 2005

Assessing biodegradation of furfuryl alcohol using Pseudomonas putida MTCC 1194 and Pseudomonas aeruginosa MTCC 1034 and its kinetics. World Journal of Microbiology & Biotechnology 34(1): 2-2, 2017

Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews 7(1): 110-110, 2018

Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Medical Oncology 28(4): 1453-1457, 2012

Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Investigation 23(3): 193-200, 2005

Small cell lung cancer analysis of treatment factors contributing to prolonged survival. Cancer 48(9): 1936-1943, 1981

Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial. Cancer Treatment Reports 69(2): 167-177, 1985

Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. Journal of Clinical Oncology 14(6): 1913-1921, 1996

Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. Journal of Thoracic and Cardiovascular Surgery 128(1): 130-137, 2004

Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer. Oncology Research and Treatment 39(3): 130-134, 2016

Effect of adjuvant central intravenous hyperalimentation on the survival and response to treatment of patients with small cell lung cancer a randomized trial. Cancer Treatment Reports 69(2): 167-178, 1985

Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 Years experience of the European Lung Cancer Working Party. European Journal of Cancer 33(14): 2326-2332, 1997